BACKGROUND: Mixed anxiety/depression is associated with poorer psychosocial and treatment outcomes, worse quality of life, pooreradherence to treatment, slower recovery, greater suicide risk, and highercost-utilization. OBJECTIVE: This study aimed to examine the cancer-specific prevalence of these symptoms. METHOD: Cross-sectional anxiety and depression symptom data were collected with the Brief Symptom Inventory from adult outpatients presenting to a tertiary cancer center (N=8,265). RESULTS: Mixed anxiety/depression symptoms were seen in 12.4% of patients; overall depression symptoms in 18.3%, overall anxiety symptoms in 24.0%, pure anxiety symptoms in 11.7%, and pure depression symptoms in 6.0%; 70% had neither. Higher rates of mixed anxiety/depression symptoms were seen with stomach, pancreatic, head and neck, and lung cancers, but lower rates were seen in those with breast cancers. The mixed anxiety/depression phenotype occurs in two-thirds of depressed cancer patients. DISCUSSION: The fact that 70% of patients did not meet thresholds for depression or anxiety symptoms can be interpreted as a reflection of the resistance to developing a significant level of these symptoms. However, because stomach, pancreatic, head and neck, and lung cancers have higher levels of mixed anxiety/depression symptoms, the question can be raised as to whether these are associated with a more biological type of anxiety/depression (e.g., due to cytokine release) and whether this phenotype should be actively targeted because of its frequent occurrence in these cancers.
BACKGROUND: Mixed anxiety/depression is associated with poorer psychosocial and treatment outcomes, worse quality of life, pooreradherence to treatment, slower recovery, greater suicide risk, and highercost-utilization. OBJECTIVE: This study aimed to examine the cancer-specific prevalence of these symptoms. METHOD: Cross-sectional anxiety and depression symptom data were collected with the Brief Symptom Inventory from adult outpatients presenting to a tertiary cancer center (N=8,265). RESULTS: Mixed anxiety/depression symptoms were seen in 12.4% of patients; overall depression symptoms in 18.3%, overall anxiety symptoms in 24.0%, pure anxiety symptoms in 11.7%, and pure depression symptoms in 6.0%; 70% had neither. Higher rates of mixed anxiety/depression symptoms were seen with stomach, pancreatic, head and neck, and lung cancers, but lower rates were seen in those with breast cancers. The mixed anxiety/depression phenotype occurs in two-thirds of depressed cancerpatients. DISCUSSION: The fact that 70% of patients did not meet thresholds for depression or anxiety symptoms can be interpreted as a reflection of the resistance to developing a significant level of these symptoms. However, because stomach, pancreatic, head and neck, and lung cancers have higher levels of mixed anxiety/depression symptoms, the question can be raised as to whether these are associated with a more biological type of anxiety/depression (e.g., due to cytokine release) and whether this phenotype should be actively targeted because of its frequent occurrence in these cancers.
Authors: Jennifer A Shin; Jesse D Kosiba; Lara Traeger; Joseph A Greer; Jennifer S Temel; William F Pirl Journal: J Pain Symptom Manage Date: 2014-04-21 Impact factor: 3.612
Authors: Angela K Lawson; Susan C Klock; Mary Ellen Pavone; Jennifer Hirshfeld-Cytron; Kristin N Smith; Ralph R Kazer Journal: J Psychosoc Oncol Date: 2015
Authors: Karen M Mustian; Calvin L Cole; Po Ju Lin; Matt Asare; Chunkit Fung; Michelle C Janelsins; Charles S Kamen; Luke J Peppone; Allison Magnuson Journal: Semin Oncol Nurs Date: 2016-10-21 Impact factor: 2.315
Authors: Catherine E Mosher; Mary A Ott; Nasser Hanna; Shadia I Jalal; Victoria L Champion Journal: Cancer Nurs Date: 2017 Jan/Feb Impact factor: 2.592
Authors: Lara Traeger; Sheila Cannon; Nancy L Keating; William F Pirl; Christopher Lathan; Michelle Y Martin; Yulei He; Elyse R Park Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Heather Greenlee; Melissa J DuPont-Reyes; Lynda G Balneaves; Linda E Carlson; Misha R Cohen; Gary Deng; Jillian A Johnson; Matthew Mumber; Dugald Seely; Suzanna M Zick; Lindsay M Boyce; Debu Tripathy Journal: CA Cancer J Clin Date: 2017-04-24 Impact factor: 508.702
Authors: Michael J Fisch; Fengmin Zhao; Judith Manola; Andrew H Miller; William F Pirl; Lynne I Wagner Journal: Psychooncology Date: 2014-06-14 Impact factor: 3.894